Effectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions

Submental Fullness

Interventions

DEVICE

Embella (Deoxycholic acid, produced by Espad Pharmed Co.)

2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid

Trial Locations (1)

Center for Research and Training in Skin Diseases and Leprosy, Tehran

All Listed Sponsors

lead

Espad Pharmed

INDUSTRY